Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.41 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5068807 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2POLBTP53ALDH1A1CYP3A4 | |
| SCHEMBL2942040 | 0.98 | SMN1; SMN2 (0.50) | SMN1; SMN2POLBTP53ALDH1A1CYP3A4 | |
| SCHEMBL3274422 | 0.98 | SMN1; SMN2 (0.50) | SMN1; SMN2POLBTP53ALDH1A1CYP3A4 | |
| SCHEMBL2942042 | 0.98 | SMN1; SMN2 (0.50) | SMN1; SMN2POLBTP53ALDH1A1CYP3A4 | |
| SCHEMBL21851141 | 0.86 | TP53 (0.56) | SMN1; SMN2POLBTP53ALDH1A1GAA | |
| SCHEMBL6032178 | 0.85 | SMN1; SMN2 (0.62) | SMN1; SMN2POLBTP53ALDH1A1CYP3A4 | |
| SCHEMBL25618622 | 0.84 | TP53 (0.46) | SMN1; SMN2POLBTP53ALDH1A1GAA | |
| SCHEMBL24837937 | 0.82 | TP53 (0.45) | SMN1; SMN2POLBTP53ALDH1A1GAA | |
| SCHEMBL2944005 | 0.82 | TP53 (0.45) | SMN1; SMN2POLBTP53ALDH1A1GAA | |
| SCHEMBL2944007 | 0.82 | TP53 (0.45) | SMN1; SMN2POLBTP53ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081817-A1 | Nitrogenous Fused Bicyclic Compound | TANABE SEIYAKU CO., LTD. (JP) | 2008-04-03 | — | — | US | disclosed |
| CN-101023083-A | Nitrogenous fused bicyclic compound | TANABE SEIYAKU CO (JP) | 2007-08-22 | — | — | CN | disclosed |
| EP-1772454-A1 | NITROGENOUS FUSED BICYCLIC COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 2007-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081817-A1 | Nitrogenous Fused Bicyclic Compound | KCNH2, KCNN2, KCNN1 | SMN1; SMN2 1970/4885POLB 2555/4885TP53 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.